Derma Genesis Calls Warning Letter A Mistake; FDA Calls Device Non-Exempt
This article was originally published in The Gray Sheet
Executive Summary
Derma Genesis is maintaining that an Oct. 31 FDA warning letter regarding commercial distribution of the Derma Peel dermabrader is the result of a misunderstanding about the firm's 510(k) premarket notification.